A division bench of the Chennai High Court has scheduled final hearing in next month over Novartis petition challenging the constitutional validity of section 3(d) of the Patents Act, 1970 and decision of the Indian Patent Office to refuse grant of patent to Novartis patent application for crystalline form of Imatinib mesylate. Justice R. Balasubramaniam of the Chennai High Court today accepted and allowed Indian Pharmaceutical Alliance, Indian Generic Manufacturer and Sun Pharmaceuticals application for impleadment. During the hearing today, Novartis wanted to place the Mashelkar Committee Report on record which was opposed by the Indian Government. Novartis also wanted to convert its writ petition filed under Article 226 of the Indian Constitution to an appeal, which was further opposed by the Indian Government and Civil Society Groups.
No comments:
Post a Comment